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The QT interval and the corrected QT interval
The QT interval is a reflection of the duration of myo­
cardial depolarization and repolarization. It is defined as 
the time between the onset of the QRS complex and the 
end of the T wave as it returns to baseline, as measured 
on the electrocardiogram (Figure 1). The QT interval is 
strongly dependent on heart rate, with ‘normal’ rate­
corrected (QTc) values considered to be between 360 and 
460 ms [1­3]. QT interval prolongation or shortening has 
been shown to be associated with an increased risk for 
life­threatening ventricular arrhythmias and sudden 
cardiac death (SCD) in familial congenital syndromes of 
long [4,5] and short QT duration [6], as well as in 
population­based samples with [7] and without [8,9] 
underlying cardiac disease. For example, Moss et al. [4] 
demonstrated that each 10 ms increase in QTc interval 
contributes to about 5% exponential increase in risk of 
cardiac events in patients with long QT syndrome 
(LQTS). Furthermore, both cardiac and non­cardiac 
drugs have been reported to prolong QT interval and 
induce arrhythmia in patients who have a QTc interval 
length within the reference range [10,11].
The QTc interval is known to be influenced by genetic 
factors, with heritability estimates between 25% and 52% 
[12­14]. In the TwinsUK study, a UK­based sample of 
mostly female twins of European ancestry, the propor­
tions of additive genetic influences have been estimated 
as 55% for resting heart rate, 60% for uncorrected QT 
interval, and 50% for QTc [15]. Until recently, research 
into genetic factors influencing QT interval was limited 
to candidate genes known to have a role in arrhythmo­
genesis, on the basis of their involvement in the con­
genital monogenic diseases LQTS and short QT syn­
drome [16­21]. However, rapid advances in biotechnology 
have now made genome­wide association (GWA) studies 
possible. In contrast to candidate gene studies in which 
genes are selected on the basis of known or suspected 
disease mechanisms, GWA studies have the potential to 
identify loci that have not been previously targeted as 
having a role in the trait or disease, thereby highlighting 
potentially novel biological pathways [22].
An early GWA study for QTc interval [23], based on 
selection of individuals from the extreme tails of the 
population­based QTc interval distribution, identified a 
common variant in the nitric oxide synthase 1 adaptor 
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protein (NOS1AP) gene region, and this has been consis­
tently confirmed in later studies [24­32]. Further more, 
variants in NOS1AP have since been associated with risk 
of SCD in two separate population­based cohorts [33,34] 
and in subjects with LQTS [35].
The NOS1AP variant has been estimated to explain up 
to only 1.5% of QTc variance [23] (Figure 2), suggesting 
the need for additional and larger GWA studies with the 
potential to detect additional common genetic variants, 
which are likely to be of more modest effect size. Recent 
efforts in this direction include meta­analyses of GWA 
studies of QT interval duration in population­based 
cohorts by a number of consortia [24­26]; these have 
contributed many newly associated loci to this complex 
trait, and have suggested a cumulative effect of individual 
variants on QT interval. Notably, the QTGEN [25] and 
QTSCD [26] consortia found that common variants in a 
number of genes previously known to cause congenital 
LQTS (KCNQ1, KCNH2, KCNE1 and KCNJ2) and short 
QT syndrome (SCN5A), were among the most strongly 
associated with QT interval in these population­based 
cohorts (Figure 2). Significantly, two of the novel loci 
con tained genes with established electrophysiological 
func tion (ATP1B1 and PLN). A third locus on 16q21 was 
near GINS3 and NDRG4, which are genes that have been 
associated with myocardial repolarization in zebrafish 
experiments [36,37], but the remaining loci fell in or near 
genes with less obvious immediate biological explana­
tions. These loci included a RING­type zinc­finger 
protein of unknown function (RNF207), a DNA­binding 
protein thought to have a role in the regulation of TNFA 
expression and which is related to a hereditary motor and 
sensory neuropathy (LITAF), and a DNA base­excision 
and repair gene (LIG3).
QT interval risk model
Given that the heritability of QTc is estimated to be about 
50%, how much of this can be explained by the common 
variants discovered so far? Based on the results of the 
combined analysis of the top hits of the QTGEN and 
QTSCD consortia, we selected the single nucleotide 
polymorphism (SNP) with strongest association in each 
of the regions (Table  1) and constructed the following 
risk model using these SNPs weighted by their estimated 
effects in the meta­analysis:
Rbeta = (1.70∙grs846111 + 3.27∙grs12143842 + 1.78∙grs10919071 + 
1.23∙grs12053903 + 1.53∙grs11970286 + 1.44∙grs4725982 + 1.62∙grs12296050 + 
1.34∙grs8049607 + 1.68∙grs37062 + 1.05∙grs2074518 + 1.10∙grs17779747)/1.61
where gSNP is the risk allele dosage of SNP, which is 
defined by: (P(0 risk alleles) × 0) + (P(1 risk allele) × 1) + 
(P(2 risk alleles) × 2); this might be a non­integer value 
when the SNP is imputed, that is, it is not genotyped 
itself but its genotype probabilities are estimated based 
on linkage disequilibrium with nearby genotyped SNPs. 
The risk allele is defined as the allele that increases the 
risk of QT interval prolongation, and hence it might be 
different from the coded allele (for example, the risk allele 
of rs12053903 in SCN5A is T and not the coded allele C; 
Table 1). The model gives more weight to SNPs with 
larger effect and is standardized in such a way that the 
risk score lies between 0 and 22, that is, the maximum 
number of risk alleles.
This model was then validated in an independent 
sample of 2,838 twins from the TwinsUK cohort; part of 
this sample (n = 1,048) had been analyzed in a GWA 
study on QTc interval [24]. We adjusted QT interval for 
the effects of RR interval, age, sex, height, body mass 
index, hypertension and QT­interval­influencing drugs, 
and used the non­standardized residuals for the genetic 
analyses. The twin cohort consisted of 2,144 dizygotic 
twins (that is, 1,072 pairs) and 694 singletons, including 
478 monozygotic twins of which the mean residual QTc 
interval of both twins was used to optimize information.
The effect of the risk model on QTc was estimated 
using linear regression while correcting the standard 
error of the regression coefficient for the twin relations 
[38,39]. The risk model was highly significantly associated 
with QTc interval (P = 2.0 × 10­31) and explained 4.7% of 
the phenotypic variance. Figure 3 shows that the length 
of the QTc interval increases with increasing genetic risk 
score, meaning that a larger number of risk alleles indeed 
predicts a longer QTc interval. For instance, individuals 
with a high genetic risk score of 15, which roughly corres­
ponds to 15 (out of 22) risk alleles, have a QTc interval of 
422.4 ± 3.3 ms, which is, on average, 17.6 ms longer than 
individuals with a low risk score of 6 (mean QTc = 
404.8 ms).
Figure 1. The surface electrocardiogram (ECG). The ECG provides 
information on the electrical events occurring within the heart, and 
is obtained by placing electrodes on the surface of the body. The 
duration of the QT interval on the ECG is defined as the duration 
between the beginning of the QRS complex and the end of the 
T wave. It is a reflection of ventricular action potential duration, and 
represents the time during which the ventricles depolarize and 
repolarize.
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Figure 2. Explained variance per risk gene for prolonging the QTc interval. The explained variance per risk gene is ordered along the x-axis 
according to year of discovery and decreasing explained variance. The green diamond represents the finding in the KORA cohort [23] (nGWA = 186, 
nGWA+replication = 6,612), the blue squares represent the findings of the QTGEN study [25] (n = 13,685), the red triangles those from the QTSCD study 
[26] (n = 15,854), and the orange circle the finding from the meta-analysis of the TwinsUK/Bright/DCCT-EDIC cohorts [24] (n = 3,558). GWA, 
genome-wide association.
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Table 1. Results of 11 single nucleotide polymorphisms selected for the risk model in the combined analysis of QTSCD 
and QTGEN
Locus Chromosome Variant Coded allele Beta Standard error P value
RNF207 1 rs846111 C 1.70 0.21 3.69 × 10-16
NOS1AP 1 rs12143842 T 3.27 0.17 1.88 × 10-78
ATP1B1 1 rs10919071 A 1.78 0.22 1.20 × 10-15
SCN5A 3 rs12053903 C -1.23 0.12 1.0 × 10-14
PLN; C6orf204 6 rs11970286 T 1.53 0.15 2.35 × 10-24
KCNH2 7 rs4725982 T 1.44 0.16 5.0 × 10-16
KCNQ1 11 rs12296050 T 1.62 0.19 2.80 × 10-17
LITAF 16 rs8049607 T 1.34 0.17 5.78 × 10-15
NDRG4; CNOT1 16 rs37062 G -1.68 0.16 3.0 × 10-25
LIG3 17 rs2074518 T -1.05 0.12 6.0 × 10-12
KCNJ2 17 rs17779747 T -1.10 0.16 6.02 × 10-12
The KCNE1 non-synonymous D85N variant rs1805128 (see also Figure 2) was not included in our risk score. It was genome-wide significant in the QTGEN study, but 
could not be confirmed in the QTSCD study and the combined analysis due to limited genotyping coverage in QTSCD.
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Future directions
In summary, the QTc genetic risk model based on the 
effects of the 11 genome­wide significant SNPs identified 
in the combined analysis of QTGEN and QTSCD was 
strongly associated with QT interval in our independent 
cohort consisting of 2,838 twins from the TwinsUK 
cohort. However, all these variants together explain only 
about 5% of the total variance in QTc, and hence about 
10% of the heritability of QTc [15].
There are a number of possible explanations for this 
[40,41]. First, GWA studies rely on the ‘common disease, 
common variant’ hypothesis [42], which suggests that 
genetic influences on many common diseases will be at 
least partly attributable to a limited number of common 
allelic variants present in more than 10% of the popu la tion. 
As discussed, GWA studies have successfully identi fied 
such variants for QTc interval [23­26]. However, to avoid 
false­positive findings, they have used extreme signifi cance 
thresholds to reliably identify these associa tions, 
potentially missing many common variants of small effect 
that did not reach the genome­wide signifi cance level. 
Detection of these additional novel variants will require 
huge sample sizes. To this end, the three existing consortia 
[24­26] and additional studies recently merged into one 
QT Interval International GWAS Consortium (QT­IGC).
Second, many important disease­causing variants may in 
fact be rare (that is, <5% or even <1%) and are unlikely to 
be detected through the GWA approach [43]. These rare 
variants may exert relatively strong phenotypic effects in 
the individuals carrying them, and may be more valuable 
in individualized risk stratification, given their greater 
predictive value [41]. The current GWA studies lack power 
to identify such rare variants with modest effect sizes.
While GWA studies have identified several novel deter­
minants of QT interval, very few functional variants have 
been identified. There is increasing evidence that many of 
the functional variants that underlie associations in GWA 
studies exert their effects through gene regulation rather 
than changing gene products. Additional resequencing of 
the genomic region of interest may be needed to identify 
the ‘causal’ variant followed by subsequent functional 
annotation studies to ascertain the clinical implications 
of these variants on arrhythmias and SCD. Progress 
towards finding these causal variants will likely increase 
the amount of heritability that can be explained. Infor­
mation on lower frequency alleles emerging from projects 
such as the 1,000 Genomes project [44] and the Personal 
Genome Project [45] will be used to produce even more 
comprehensive GWA arrays, and will facilitate the 
investigation of the lower frequency variants without the 
need for de novo sequencing. The use of next­generation 
sequencing platforms, which provide high­volume 
sequence data with costs for resequencing exonic regions 
of the genome now approaching those for GWA studies, 
will also no doubt play a role in achieving this goal.
The problem of missing heritability may also be partially 
solved using an approach whereby many of the hits from a 
GWA study are followed up, rather than the current 
practice of carrying out meta­analyses and extensive 
follow­up of only the top ranked hits. This approach was 
successfully employed in a recent GWA study of celiac 
disease [46,47]. By taking advantage of the ever­decreasing 
price of genotyping, one might simultaneously follow up in 
a large replication sample, for example, 1,536 loci, a typical 
panel for one common platform, in a single experiment.
To date, the primary study population of published 
GWA studies has been of European origin. Therefore, 
there is also a need to extend association analyses to 
diverse non­European populations to confirm association 
signals identified thus far, as well as to potentially identify 
novel association signals [48,49] and etiological pathways.
Analyzing existing QT GWA study datasets with 
computational tools and pathway databases rather than 
considering only genes or gene variants may well further 
increase our understanding of the genetic architecture of 
this complex trait. Future and existing QT GWA study 
results have and will continue to identify important and 
potentially novel biochemical pathways for patho physio­
logy and therapeutics. Results have already pointed 
toward a greater emphasis on ion channels, which have 
long been known to be involved in congenital LQTS, and 
more recently to the nitric oxide pathway. Indeed a recent 
study found that SNPs in the NOS1AP gene modify the 
QT, prolonging effects of certain drugs [50].
Figure 3. Correlation between genetic risk score and QT interval. 
The bars show the distribution of the risk score classes (left axis). In 
pink, a plot of the risk score versus unstandardized QT residual is 
given, and the blue line shows the means of the unstandardized QT 
residual within risk score classes (right axis). Error bars represent the 
standard errors of the means.
0
100
200
300
400
500
0
370
390
410
430
450
470
490
N
um
be
r 
of
 in
di
vi
du
al
s
0 5 10 15 20
Genetic risk score
A
dj
us
te
d 
Q
T
 in
te
rv
al
 (
m
s)
Jamshidi et al. Genome Medicine 2010, 2:35 
http://genomemedicine.com/content/2/5/35
Page 4 of 7
Newly identified risk genes can therefore potentially 
advance drug development by highlighting novel thera­
peutic targets, or refocusing existing efforts for drug 
development to target, for example, the ion channel gene 
pathways. Furthermore, genetic profiling might advance 
drug development by identifying participants most likely 
to benefit from, or least likely to experience adverse 
effects of, a targeted therapeutic approach.
Due to the generally small effect sizes of the markers 
identified through GWA studies, much of the genetic 
data generated will not be of great value in isolation, but 
should rather be interpreted within the context of a 
predictive score, ideally complemented with information 
on non­genetic/environmental risk exposures, to allow 
targeted medical intervention before the onset of symp­
toms. The viability of this application might be limited, 
however, because the currently identified genes only 
explain a small proportion of the heritability. This reflects 
the complexity of translating markers identified through 
population studies into reliable predictors at an indivi­
dual level. The diagnostic utility of genetic profiling also 
appears to be limited in other common complex diseases 
and traits. For example, a 54­locus genetic profile for the 
highly heritable trait height could predict only 4 to 6% of 
variation in height compared with 40% by traditional 
predictions based on parental height [51]. In fact, 
although GWA studies have been very successful in 
identi fy ing specific loci and/or genomic regions that 
contribute to QTc and many other phenotypes, there has 
been some disappointment that only a small proportion 
of the heritability of many conditions has been accounted 
for [52,53]. However, it is important to remember that 
the main goal of GWA studies has never been disease 
predic tion, but rather the discovery of biological path­
ways underlying polygenic disease or traits.
Despite the problems of ‘missing heritability’, associated 
loci identified from GWA studies can yield, and are 
already yielding, important insights into disease etiology, 
as well as potential drug targets. In the context of QT 
interval, the novel implication of a biochemical pathway 
such as the nitric oxide pathway in repolarization and 
arrhythmogenesis has already led to the suggestion that it 
is no longer sufficient to focus on the electrical properties 
of the heart when attempting to link genetic variation to 
cardiac arrhythmias. Rather, scientists and clinicians 
should now also consider electrical remodeling in res­
ponse to environmental factors which can be controlled 
by the expression and activity of signaling molecules such 
as NOS1AP.
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